
Brynn Marks, MD, MSHPEd, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss a new framework defining fully closed loop insulin delivery.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Brynn Marks, MD, MSHPEd, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss a new framework defining fully closed loop insulin delivery.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss dosing guidelines for the recently approved efsitora alfa-gobe.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's approval of a new basal insulin for T2D.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss UACR screening for patients with CKD and T1D.

Discover how newly cleared weekly basal insulin efsitora reshapes type 2 diabetes care—QWINT results, hypoglycemia edge, and dosing tips.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of finerenone for CKD with T1D.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.

In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Casey Halpern, MD, to discuss SynchNeuro's investigational, non-invasive EEG-based glucose monitor.

In this episode, co-hosts Isaacs and Bellini are joined by Eden Miller, DO, and Davida Kruger, NP, to discuss the FDA's recent clearance of the FreeStyle Libre Duo ketone monitor.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

This episode discusses the recent results from trials of IcoSema and a new highly concentrated insulin aspart.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss switching patients from basal insulin to Awiqli.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the promise of continuous ketone monitoring in T1D.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new insulin pump technology presented at ADCES 2026.

Once-weekly insulin icodec hits US pharmacies, simplifying basal dosing for type 2 diabetes with new titration rules and promising A1c results.

Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

This episode covers the recently announced topline data from the TRIUMPH-2 and TRIUMPH-3 phase 3 trials, as well as a study investigating online GLP-1 sales.

This episode covers the recent commercial availability of the Pivot patch pump and the upcoming 7-day bolus patch from CeQur.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover recent data released by Eledon regarding tegoprubart for type 1 diabetes.

This episode covers the recent release of new data on Eledon’s tegoprubart for islet cell transplantation in patients with T1D.

August 24th 2022

January 16th 2023

February 27th 2024